Badrish Patel
Christiana Care Health System
6 Papers
3 Citations
Badrish Patel is an academic researcher from Christiana Care Health System. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 3 publications.
Chat about Author
Papers
An Interdepartmental Care Model to Expedite Admission from the Emergency Department to the Medical ICU.
Daniel J. Elliott,Kimberly D. Williams,Pan Wu,Hemant V. Kher,Barret Michalec,Natalie Reinbold,Christian M. Coletti,Christian M. Coletti,Christian M. Coletti,Badrish Patel,Robert Dressler +10 more
TL;DR: Early outcomes demonstrate that the MAT intervention can reduce ED LOS for critically ill patients, and additional studies should determine optimal approaches to improve clinical outcomes.
23
Therapy with Allogeneic SARS-CoV-2-specific T-cells for Persistent COVID-19 in Immunocompromised Patients.
Ghady Haidar,Jana L. Jacobs,K. Hughes Kramer,Asma Naqvi,Amy Heaps,Urvi M. Parikh,Kevin McCormick,Michele D. Sobolewski,Mounzer E. Agha,Tatiana Bogdanovich,Vasilii Bushunow,Rafic Farah,Matthew K. Hensley,Y.-S. Hsu,Cynthia Klamar-Blain,Jennifer M Kozar,Elizabeth A. Lendermon,Bernard J.C. Macatangay,Anastasios Raptis,Fernanda P. Silveira,Ann M. Leen,William L. Marshall,Badrish Patel,Ercem S. Atillasoy,John W. Mellors +24 more
TL;DR: In this paper , SARS-CoV-2 VST was administered to 6 immunocompromised patients with persistent COVID-19 and characterized clinical and virologic responses: three patients had partial responses after failing other therapies but then died.
983: sensitivity and positive predictive value of cerner emr based sepsis recognition tool
TL;DR: It was concluded that the Cerner algorithm for sepsis recognition suffers from low sensitivity and has only slightly higher positive predictive value than SIRS criteria for detecting sepsi.
3
2161. Posoleucel, an Allogeneic, Off-the-Shelf Multi-Virus Specific T Cell Therapy, for Severe, Drug-Refractory Viral Infections in Pediatric Patients Following HCT: Results from a Phase 2 Trial
Thomas Pfeiffer,Ifigeneia Tzannou,Carlos A. Ramos,Ghadir S. Sasa,Caridad Martinez,Premal Lulla,R. Krance,Swati Naik,Iain P Fraser,Marshelle Warren,Badrish Patel,Dany Ward,Ann M. Leen,Bilal Omer +13 more
TL;DR: Tzannou et al. as mentioned in this paper presented the efficacy and safety data in pediatric patients (< 18 years) enrolled in CHARMS and showed that PSL treatment was generally well tolerated.
Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting
Thomas Pfeiffer,Ifigeneia Tzannou,Meng-Fen Wu,Carlos A. Ramos,Ghadir S. Sasa,Caridad Martinez,Premal Lulla,Robert A. Krance,Lauren D. Scherer,Daniel Ruderfer,Swati Naik,Claire E. Bocchini,Iain P Fraser,Badrish Patel,Dany Ward,Tao Wang,Helen E. Heslop,Ann M. Leen,Bilal Omer +18 more
TL;DR: In this paper , the authors conducted an open-label, phase II trial to determine the feasibility and safety of posoleucel in allogeneic hematopoietic cell transplantation (allo-HCT) recipients infected with one or more of these viruses.